Breast Cancer Clinical Trial

Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer

Summary

The purpose of this study is to evaluate whether treatment to the axilla (area under the arm) can be safely minimized by omitting axillary surgery and full axillary radiation therapy and replacing it with radiation therapy to the breast and lower axilla.

View Full Description

Full Description

Patients will have undergone conservative breast surgery without axillary dissection prior to enrollment in this study.
Patients will receive radiation therapy to the breast, including the lowest axillary lymph nodes, over a period of 6 1/2 weeks.
No radiation will be specifically directed toward the upper axilla or supraclavicular lymph nodes.
Patients will also receive 5 years of tamoxifen or another type of hormone therapy determined by the medical oncologist.
Follow-up visits will occur every 6 months and mammograms every 12 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have clinical stage I or II breast cancer, clinically uninvolved axillary nodes.
Patients must be 55 years or older.
Patients must undergo total excision of the primary invasive tumor
Final pathologic margin status must be negative
Only estrogen receptor (ER) or progesterone receptor (PR) positive tumors will be permitted

Exclusion Criteria:

Prior history of malignancy, except for non-melanoma skin cancers and carcinoma in situ fo the cervix

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

100

Study ID:

NCT00165243

Recruitment Status:

Completed

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dana-Farber Cancer Institute
Boston Massachusetts, 02115, United States
Massachusetts General Hospital
Boston Massachusetts, 02115, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

100

Study ID:

NCT00165243

Recruitment Status:

Completed

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider